{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Retinal+Disease&page=43",
    "query": {
      "condition": "Retinal Disease",
      "page": 43
    },
    "page_size": 10
  },
  "pagination": {
    "page": 43,
    "page_size": 10,
    "total_count": 1620,
    "total_pages": 162,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Retinal+Disease&page=44&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Retinal+Disease&page=42&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T03:12:20.701Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02555306",
      "title": "A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "0.5 mg of DE-122",
          "type": "DRUG"
        },
        {
          "name": "1.0 mg of DE-122",
          "type": "DRUG"
        },
        {
          "name": "2.0 mg of DE-122",
          "type": "DRUG"
        },
        {
          "name": "4.0 mg of DE-122",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Santen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2015-09-16",
      "completion_date": "2017-08",
      "has_results": true,
      "last_update_posted_date": "2020-01-14",
      "last_synced_at": "2026-10-29T03:12:20.701Z",
      "location_count": 5,
      "location_summary": "Mountain View, California • Walnut Creek, California • Jackson, Michigan + 2 more",
      "locations": [
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Jackson",
          "state": "Michigan"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "McAllen",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02555306"
    },
    {
      "nct_id": "NCT01085734",
      "title": "Single Site, Masked, Randomized, Controlled Study to Assess Efficacy of Osurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Macular Edema Due to Central or Branch Retinal Vein Occlusion",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Retinal Vein Occlusions"
      ],
      "interventions": [
        {
          "name": "Avastin",
          "type": "DRUG"
        },
        {
          "name": "Osurdex",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Maturi, Raj K., M.D., P.C.",
      "sponsor_class": "INDIV",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2010-03",
      "completion_date": "2011-10",
      "has_results": true,
      "last_update_posted_date": "2014-04-21",
      "last_synced_at": "2026-10-29T03:12:20.701Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01085734"
    },
    {
      "nct_id": "NCT04234932",
      "title": "Short-term Effect of Rho-kinase Inhibitor on Retinal Circulation",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Glaucoma, Open-Angle"
      ],
      "interventions": [
        {
          "name": "Netarsudil Ophthalmic",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of the Incarnate Word",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2020-01-06",
      "completion_date": "2021-01",
      "has_results": false,
      "last_update_posted_date": "2020-04-14",
      "last_synced_at": "2026-10-29T03:12:20.701Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04234932"
    },
    {
      "nct_id": "NCT02681809",
      "title": "A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Retinopathy",
        "Posterior Vitreous Detachment",
        "Disease Progression"
      ],
      "interventions": [
        {
          "name": "ocriplasmin 0.0625mg",
          "type": "DRUG"
        },
        {
          "name": "ocriplasmin 0.125mg",
          "type": "DRUG"
        },
        {
          "name": "Sham injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ThromboGenics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2015-12",
      "completion_date": "2019-11-18",
      "has_results": true,
      "last_update_posted_date": "2020-12-16",
      "last_synced_at": "2026-10-29T03:12:20.701Z",
      "location_count": 9,
      "location_summary": "Phoenix, Arizona • Campbell, California • Irvine, California + 6 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02681809"
    },
    {
      "nct_id": "NCT02420132",
      "title": "Study to Evaluate Home Vision Testing in Participants Who Receive Ranibizumab (Lucentis®)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Macular Edema",
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Ranibizumab",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2015-04-20",
      "completion_date": "2016-08-25",
      "has_results": false,
      "last_update_posted_date": "2019-06-10",
      "last_synced_at": "2026-10-29T03:12:20.701Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02420132"
    },
    {
      "nct_id": "NCT00000693",
      "title": "Suppression of Cytomegalovirus Retinitis Utilizing High Dose Intravenous Acyclovir and Oral Zidovudine in Patients With AIDS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cytomegalovirus Retinitis",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Zidovudine",
          "type": "DRUG"
        },
        {
          "name": "Acyclovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 25,
      "start_date": null,
      "completion_date": "1992-03",
      "has_results": false,
      "last_update_posted_date": "2021-11-02",
      "last_synced_at": "2026-10-29T03:12:20.701Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000693"
    },
    {
      "nct_id": "NCT00805233",
      "title": "Combination Ranibizumab and Bromfenac for Neovascular Age-related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "combination ranibizumab + bromfenac",
          "type": "DRUG"
        },
        {
          "name": "ranibizumab injection alone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2008-12",
      "completion_date": "2010-09",
      "has_results": false,
      "last_update_posted_date": "2011-07-22",
      "last_synced_at": "2026-10-29T03:12:20.701Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00805233"
    },
    {
      "nct_id": "NCT00354445",
      "title": "A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Age-Related Macular Degeneration (AMD)"
      ],
      "interventions": [
        {
          "name": "pegaptanib sodium (Macugen)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eyetech Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 1000,
      "start_date": "2006-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2007-01-15",
      "last_synced_at": "2026-10-29T03:12:20.701Z",
      "location_count": 1,
      "location_summary": "Abilene, Texas",
      "locations": [
        {
          "city": "Abilene",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00354445"
    },
    {
      "nct_id": "NCT00406107",
      "title": "Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Branch Retinal Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "pegaptanib sodium (Macugen)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Palmetto Retina Center, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2006-01",
      "completion_date": "2008-04",
      "has_results": true,
      "last_update_posted_date": "2014-09-12",
      "last_synced_at": "2026-10-29T03:12:20.701Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Hagerstown, Maryland • West Columbia, South Carolina",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Hagerstown",
          "state": "Maryland"
        },
        {
          "city": "West Columbia",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00406107"
    },
    {
      "nct_id": "NCT01486771",
      "title": "Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Proliferative Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "Macugen ® (pegaptanib sodium)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Valley Retina Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2007-11",
      "completion_date": "2014-02",
      "has_results": false,
      "last_update_posted_date": "2011-12-06",
      "last_synced_at": "2026-10-29T03:12:20.701Z",
      "location_count": 1,
      "location_summary": "McAllen, Texas",
      "locations": [
        {
          "city": "McAllen",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01486771"
    }
  ]
}